Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shintaro Hirata

Showing results (111-120 of 151) with videos related to

Pageof 16
Sort By:
Modern Rheumatology|March 21, 2024
Consensus statement on the management of late-onset rheumatoid arthritisMasayo Kojima, Takahiko Sugihara, Yutaka Kawahito, et al.
Modern Rheumatology|September 12, 2014
Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeksHiroto Tsuboi, Isao Matsumoto, Shinya Hagiwara, et al.
Clinical and Experimental Rheumatology|September 26, 2025
Circulating microRNAs associated with tumour necrosis factor or fibloblast-like synoviocyte predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE studyYohei Hosokawa, Yusuke Yoshida, Hiroya Tamai, et al.
The Lancet. Rheumatology|January 22, 2024
Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
Annals of the Rheumatic Diseases|March 24, 2017
Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren's syndrome with other sets of criteria in Japanese patientsHiroto Tsuboi, Shinya Hagiwara, Hiromitsu Asashima, et al.
Annals of the Rheumatic Diseases|October 4, 2024
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
Modern Rheumatology|July 27, 2016
Effectiveness of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy) trialHiroto Tsuboi, Isao Matsumoto, Shinya Hagiwara, et al.
Rheumatology (Oxford, England)|February 9, 2022
Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J studyYoshiya Tanaka, Ayako Yamaguchi, Toshiaki Miyamoto, et al.
Annals of the Rheumatic Diseases|January 28, 2025
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
Annals of the Rheumatic Diseases|October 21, 2019
Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trialYoshiya Tanaka, Koji Oba, Takao Koike, et al.
Pageof 16

Showing results (111-120 of 151) with videos related to

Sort By:
Pageof 16
Modern Rheumatology|March 21, 2024
Consensus statement on the management of late-onset rheumatoid arthritisMasayo Kojima, Takahiko Sugihara, Yutaka Kawahito, et al.
Modern Rheumatology|September 12, 2014
Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeksHiroto Tsuboi, Isao Matsumoto, Shinya Hagiwara, et al.
Clinical and Experimental Rheumatology|September 26, 2025
Circulating microRNAs associated with tumour necrosis factor or fibloblast-like synoviocyte predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE studyYohei Hosokawa, Yusuke Yoshida, Hiroya Tamai, et al.
The Lancet. Rheumatology|January 22, 2024
Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
Annals of the Rheumatic Diseases|March 24, 2017
Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren's syndrome with other sets of criteria in Japanese patientsHiroto Tsuboi, Shinya Hagiwara, Hiromitsu Asashima, et al.
Annals of the Rheumatic Diseases|October 4, 2024
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
Modern Rheumatology|July 27, 2016
Effectiveness of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy) trialHiroto Tsuboi, Isao Matsumoto, Shinya Hagiwara, et al.
Rheumatology (Oxford, England)|February 9, 2022
Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J studyYoshiya Tanaka, Ayako Yamaguchi, Toshiaki Miyamoto, et al.
Annals of the Rheumatic Diseases|January 28, 2025
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
Annals of the Rheumatic Diseases|October 21, 2019
Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trialYoshiya Tanaka, Koji Oba, Takao Koike, et al.
Pageof 16